Medovex Enters Into Service Agreement With LNE/G-MED for

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Medovex Enters Into Service Agreement With LNE/G-MED for Regulatory Services in Preparation for CE Marking

ATLANTA, GA--(Marketwired - Apr 7, 2016) - Medovex Corp. ( NASDAQ : MDVX ), a developer of medical technology products, today announced that it has entered into a service agreement with a leading Notified Body regulatory firm, France based, LNE/G-Med, for its pathway for the DenerveX™ System to the CE Mark for the EU.

According to Patrick Kullmann, President and COO of Medovex, "The development of our DenerveX System continues to advance. Currently being addressed are certain final design and development elements of the product, which we believe will ultimately lead to gaining regulatory approval in the European Union (EU) counties that require the CE mark." 

Kullmann concluded, "Before you can offer for sale your medical products in nations within the (EU) and the European Free Trade Association, you must first satisfy the requirements for CE Marking, a conformity mark that signifies a product has met all criteria of the relevant EU directives, especially in the areas of safety and performance. We are pleased to be working with LNE/G-MED toward this goal being a leading Notified Body in the EU with a strong history of assisting medical technologies in the CE Mark process."

The Company's patented DenerveX System, currently in final development is designed to provide longer lasting relief of pain associated with the facet joint. Lower back pain is the second most common cause of disability in the U.S. for adults. Studies indicate that 10% of the U.S. adult population suffers from lower back pain and that 31% of lower back pain is attributed to facet joint pain.

The DenerveX System consists of the DenerveX device, a single use device, and the DenerveX Pro-40 Power Generator. The DenerveX system is designed to provide a minimally invasive treatment option which combines two actions into one device.

DenerveX is not yet CE marked or FDA cleared and is not yet commercially available.

About Medovex

Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company's first pipeline product, the DenerveX device, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. To learn more about Medovex Corp., visit www.medovex.com

About LNE/G-MED

LNE/G-MED is committed to providing Medical Device manufacturers with the knowledge and tools to create the Regulatory and Technical solutions they need to ensure Quality, Expertise, Speed and Innovation during their certification. The synergy between our American and European-based pool of Experts allow us to guide you to efficient solutions to your Domestic and International regulatory and Technical challenges. With over 11 local offices, LNE/G-MED offers its expertise and services to help you maintain control and compliance with the regulations affecting your products. For more information, please visit www.lne-america.com

Safe Harbor Statement

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

CONTACT INFORMATION Medovex Corp. Jason Assad 470-505-9905 Email Contact

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Auria, LSAS Team Up: Japan Space Frontier Beckons

Updated Category News Views 105

Pioneering Ventures in Japan's Space Race Watch out, folks—Auria and LSAS Tec have something cooking. One's a titan in space technology, and the other's a maestro in mission analysis. They're joining forces to tango in Japan's booming space market. If you're into the street-smart equity dance, this partnership ain't just chatter over coffee; it's a leap toward new...

Continue Reading
Linux Foundation Unveils the Global Fraud Alliance

Updated Category News Views 99

Who would have thought the tech wizards at the Linux Foundation would step up to tackle fraud on a global scale? That's what we've got with their latest play: the Open Financial Trust Alliance (OFTA). Launched at the Singapore FinTech Festival, they've got their sights on connecting the world's disconnected fraud fight. Think of it as a translator for the tangled mess of...

Continue Reading
Madrigal Pharmaceuticals Faces Legal Scrutiny Over Data

Updated Category News Views 152

Legal Storm Brews for Madrigal Pharmaceuticals Watch out, here comes another storm for Madrigal Pharmaceuticals, folks. This ain't no small drizzle either; it's a full-on legal monsoon, and it's soaked straight through the walls of their executive suite. We're talking a whistleblower sending alarm bells ringing about data fudging and some dodgy boardroom maneuvers—as if...

Continue Reading
Universal Haptics Protocol May Cut Integration Friction

Updated Category News Views 301

A controller rumbling at the wrong moment is a small annoyance, but the plumbing behind that rumble has been a stubborn mess for years. The Haptics Industry Forum's Universal Haptics Protocol 1.0, announced November 17, 2026, is an attempt to clean up that mess with a shared language between software and touch-feedback hardware. This is not the sort of release that sends...

Continue Reading
Azazie Tests Bridal Demand With Two East Coast Pop-Ups

Updated Category News Views 116

Wedding dresses are a miserable product to buy sight unseen, no matter how pretty the product photos look. That basic fact is why Azazie’s two East Coast pop-ups on November 21 and 22 deserve a closer look. This is not some grand retail rollout, and nobody should pretend a pair of short events rewrites the bridal market. But it is a practical test of where a...

Continue Reading
Iberostar's Grand Move: Opening in Zanzibar

Updated Category News Views 135

The Resort That Takes Your Breath Away Here we have Iberostar, boldly wading into the azure waters of the Indian Ocean, planting its flag on the sandy beaches of Zanzibar. This isn’t just another notch on the resort’s belt—it’s their first time setting up shop in East Africa, a move ripe with promise and adventure both. A Suite So Sweet 358 suites, mind you. Each...

Continue Reading
Stand Out For Good Makes a Bold Michigan Avenue Bet

Updated Category News Views 183

A six-floor retail commitment lands with a thud Stand Out For Good is taking on roughly 51,079 square feet at 669 North Michigan Avenue, and nobody should mistake that for a casual expansion. Six levels on Chicago's Magnificent Mile is a proper declaration of intent, especially in a retail district that has endured plenty of empty-window handwringing and big-brand churn....

Continue Reading
Clorox Boosts Payout With Steady $1.25 Dividend

Updated Category News Views 165

Quarterly Dividends: A Clorox Tradition It seems you can't talk about Clorox (NYSE: CLX) without mentioning its steadfast dedication to shareholders. Once again, this 113-year-old stalwart is back on the map with its juicy quarterly dividend—$1.25 per share, to be precise. That's scheduled to hit your account by February 12, 2027, if you're on the books by the end of...

Continue Reading
Thoughts Unleashed Arrives With a Personal American Voice

Updated Category News Views 114

A lifetime of observation finally gets its own page Forty is an unusual age to begin writing poetry, which is exactly why Joyce Ann Grooms McGeehan's debut has a little more texture than the usual polished promise of inspiration. Thoughts Unleashed by an Independent, American Woman comes from someone who spent decades teaching French, English, and ESL, then retired to a...

Continue Reading
Legato Frames Put Tiny AI to a Real-World Hearing Test

Updated Category News Views 156

A hearing aid that never enters the ear is a deceptively brutal product challenge. It has to hear speech through a mess of restaurant clatter, traffic, wind and ordinary human commotion; it has to run all day; and, crucially, it cannot look like a medical concession somebody reluctantly straps on. Legato Frames are aiming right at that knot, with femtoAI providing the...

Continue Reading

Top 5 Most Recently Viewed Articles

US LBM Expands Reach with Strategic Milton Truss Acquisition

Updated Category News Views 423

US LBM Welcomes Milton Truss to Its Family US LBM, a leading distributor of specialty building materials, has made a significant move by acquiring Milton Truss, a well-respected manufacturer specializing in structural building components. This acquisition expands US LBM’s operational capabilities and strengthens its presence in the Southeast, particularly within the...

Continue Reading
US Residential Construction Market Shows Promising Growth Ahead

Updated Category News Views 332

The Future of the US Residential Construction Market The residential construction market in the United States is poised to experience significant growth, with estimates suggesting an increase of USD 242.9 million from 2025 to 2029. As household formation rates rise, there is an unmistakable trend towards building more residential units, coupled with an increasing emphasis...

Continue Reading
Orbital Amplifies Currency Reach with Banking Circle

Updated Category News Views 30

Unpacking Orbital's New Alliance with Banking Circle Today's chat's all about payments—specifically how Orbital's rolling out the red carpet with Banking Circle to ramp up their multi-currency payment interface. The company's stretching its limbs into the Nordics, Central Europe, Switzerland, and Australia. With a suit like this, Orbital's not just dropping coins into...

Continue Reading
Jorge Blanco's Achievement Acknowledged as 2025 CRE Tech Influencer

Updated Category News Views 466

Jorge Blanco Celebrated as a 2025 CRE Tech Influencer Altus Group Limited (TSX: AIF), a leading force in asset and fund intelligence for the commercial real estate sector, is excited to announce that its Chief Commercial Officer, Jorge Blanco, has received recognition as a 2025 CRE Technology Influencer. This accolade comes from a renowned publication dedicated to...

Continue Reading
Investor Concerns Rise for Unicycive Therapeutics (UNCY) Amid Investigation

Updated Category News Views 200

Investigating Securities Concerns at Unicycive Therapeutics In the fast-paced world of pharmaceuticals, investor sentiment can shift dramatically based on the health of the company and news that emerges. Currently, Unicycive Therapeutics, Inc. (NASDAQ: UNCY) is facing scrutiny as Pomerantz LLP has initiated an investigation concerning potential claims on behalf of its...

Continue Reading